Stockscreener 앱 받기
0.9606
0.44%
-0.0042
시간 외 거래:
.98
0.0194
+2.02%
전일 마감가:
$0.9648
열려 있는:
$0.9793
하루 거래량:
375.18K
Relative Volume:
0.50
시가총액:
$103.37M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-3.6318
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
+9.91%
1개월 성능:
-3.18%
6개월 성능:
-4.89%
1년 성능:
+5.04%
1일 변동 폭
$0.96
$0.9999
1주일 범위
$0.91
$1.00
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9606 | 103.82M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - Investing News Network
Oncolytics Biotech expands GI cancer advisory board with three experts By Investing.com - Investing.com Nigeria
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials - TipRanks
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
What drives Oncolytics Biotech Inc stock priceStock Rotation Strategies & Big Profit Small Investment - earlytimes.in
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1.5%Here's Why - MarketBeat
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting - ACCESS Newswire
Revenue per share of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView — Track All Markets
What hedge fund activity signals for Oncolytics Biotech Inc. stockWeekly Profit Recap & Technical Pattern Based Signals - Улправда
Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - Улправда
Published on: 2025-12-20 04:27:06 - Улправда
Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber
Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber
What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - Улправда
Quarterly Risk: Is Oncolytics Biotech Inc. stock a buy for dividend growthTrend Reversal & Fast Entry High Yield Stock Tips - Улправда
Published on: 2025-12-18 16:49:38 - Улправда
Lake Street Remains a Buy on Oncolytics Biotech (ONCY) - The Globe and Mail
[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan
Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
Oncolytics Biotech says data backs pelareorep in KRAS-mutant mCRC - marketscreener.com
Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer By Investing.com - Investing.com South Africa
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis - GlobeNewswire Inc.
United States Oncolytic Virus Therapy Market to Reach USD 199.98 - openPR.com
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Cantech Letter
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion - The Globe and Mail
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Oncolytics Biotech plans jurisdiction shift to Nevada - MSN
Oncolytics Biotech Plans Jurisdiction Shift to Nevada - The Globe and Mail
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move By Investing.com - Investing.com Nigeria
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporat - pharmiweb.com
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - The AI Journal
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move - Investing.com
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):